Pharmacological treatment of fibromyalgia;La terapia farmacologica della fibromialgia

Reumatismo

Volumn 59, Issue 4, 2007, Pages 280-291

  Cazzola, M ^a   Sarzi Puttini, P ^b   Buskila, D ^c   Atzeni, Fabiola ^b  

^a BUSTO ARSIZIO HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c BEN GURION UNIVERSITY OF THE NEGEV   (Israel)

Author keywords

Fibromyalgia syndrome; Management of fibromyalgia; Pharmacological treatment

Indexed keywords

AMITRIPTYLINE; ANTICONVULSIVE AGENT; ANTIINFLAMMATORY AGENT; CITALOPRAM; CYCLOBENZAPRINE; DESIPRAMINE; DULOXETINE; FLUOXETINE; GABAPENTIN; IMIPRAMINE; LIDOCAINE; MILNACIPRAN; MIRTAZAPINE; MORPHINE; NALOXONE; NORTRIPTYLINE; PARACETAMOL PLUS TRAMADOL; PAROXETINE; PLACEBO; PREGABALIN; REBOXETINE; ROPINIROLE; SEROTONIN NORADRENALIN REUPTAKE INHIBITOR; TRAMADOL; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE; ZOLPIDEM; ZOPICLONE; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; ANALGESIC AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; IMMUNOLOGICAL ADJUVANT; NARCOTIC ANALGESIC AGENT; SEROTONIN UPTAKE INHIBITOR;

ANTICHOLINERGIC EFFECT; ASTHENIA; CHRONIC PAIN; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONVULSION; DRUG EFFICACY; FIBROMYALGIA; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; INSOMNIA; LIBIDO DISORDER; MIDDLE AGED; MONOTHERAPY; MYALGIA; NAUSEA; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; SOMNOLENCE; URINE RETENTION; AGE; DRUG COMBINATION; FEMALE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; SEX DIFFERENCE; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; AGE FACTORS; ANALGESICS; ANALGESICS, OPIOID; ANTI-INFLAMMATORY AGENTS; ANTICONVULSANTS; ANTIDEPRESSIVE AGENTS, TRICYCLIC; DOPAMINE AGONISTS; DRUG THERAPY, COMBINATION; FEMALE; FIBROMYALGIA; GABA AGONISTS; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; SEROTONIN UPTAKE INHIBITORS; SEX FACTORS; TREATMENT OUTCOME;

EID: 55449108369     PISSN: 00487449     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (78)

1. Mease P. Fibromyalgia syndrome: review of clinical presentation, pathogenesis, outcome measures, and treatment. J Rheumatol 2005; 75: 6-21.
2. Nampiaparampil DE, Shmerling RH. A review of fibromyalgia. Am J Manag Care 2004; 10: 794-800.
3. Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, et al. The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the multicenter criteria committee. Arthritis Rheum1990; 33: 160-72.
4. Benjamin S, Morris S, McBeth J, Macfarlane GJ, Silman AJ, et al. The association between chronic widespread pain and mental disorder: a population-based study. Arthritis Rheum 2000; 43: 561-7.
5. Bennett RM. Adult growth hormone deficiency in patients with fibromyalgia. Curr Rheumatol Rep 2002; 4: 306-12.
6. Sarzi-Puttini P, Atzeni F, Diana A, Doria A, Furlan R. Increased neural sympathetic activation in fibromyalgia syndrome. Ann NY Acad Sci 2006; 1069: 109-17.
7. Rizzi M, Sarzi-Puttini P, Atzeni F, Capsoni F, Andreoli A, Pecis M, et al. Cyclic alternating pattern: a new marker of sleep alteration in patients with fibromyalgia? J Rheumatol 2004; 31: 1193-9.
8. Furlan R, Colombo S, Perego F, Atzeni F, Diana A, Barbic F, et al. Abnormalities of cardiovascular neural control and reduced orthostatic tolerance in patients with primary fibromyalgia. J Rheumatol 2005; 32: 1787-93.
9. Robinson RL, Birnbaum HG, Morley MA, Sisitsky T, Greenberg PE, Claxton AJ. Economic cost and epidemiological characteristics of patients with fibromyalgia claims. J Rheumatol 2003; 30: 1318-25.
10. Rao SG, Clauw DJ. The management of fibromyalgia. Drugs Today 2004; 40: 539-54.
11. Goldenberg DL, Burckhardt C, Crofford L. Management of fibromyalgia syndrome. JAMA 2004; 292: 2388-95.
12. Baker K, Barkhuizen A. Pharmacologic treatment of fibromyalgia. Curr Pain Headache Rep 2005; 9: 301-6.
13. Crofford LJ. Pharmaceutical treatment options for fibromyalgia. Curr Rheumatol Rep 2004; 6: 274-80.
14. Maizels M, McCarberg B. Antidepressants and antiepileptic drugs for chronic non-cancer pain. Am Fam Physician 2005; 71: 83-490.
15. O'Malley PG, Balden E, Tomkins G, Santoro J, Kroenke K, Jackson JL. Treatment of fibromyalgia with antidepressants: a meta-analysis. J Gen Intern Med 2000; 15: 659-66.
16. Carette S, Mccain GA, Bell DA, Fam AG. Evaluation of amitriptyline in primary fibrositis. Arthritis Rheum 1986; 29: 655-9.
17. Carette S, Bell MJ, Reynolds WJ, Haraoui B, McCain GA, Bykerk VP, et al. Comparison of amitriptyline, cyclobenzaprine, and placebo in the treatment of fibromyalgia: a randomized, placebo-controlled, doubleblind, clinical trial. Arthritis Rheum 1994; 37: 32-40.
18. Goldenberg DL, Felson DT, Dinerman H. A randomized, controlled trial of amitriptyline and naproxen in the treatment of patients with fibromyalgia. Arthritis Rheum 1986; 29: 1371-7.
19. Santandrea S, Sarzi-Puttini P, Boccassini L, Caruso I. A double blind crossover study of two cyclobenzaprine regimens in primary fibromyalgia syndrome. J Int Med Res 1993; 21: 74-80.
20. Tofferi JK, Jackson JY, O'Malley PG. Treatment of fibromyalgia with cyclobenzaprine: a meta-analysis. Arthritis Rheum 2004; 51: 9-13.
21. Arnold LM, Keck PE: Antidepressant treatment of fibromyalgia: a meta-analysis and review. Psychosomatics 2000; 41: 104-13.
22. Hannonen P, Malminiemi K, Yli-Kerttula U, Isomeri R, Roponen P. A randomized, double-blind, placebo-controlled study of moclobemide and amitriptyline in the treatment of fibromyalgia in females without psychiatric disorder. Br J Rheumatol 1998; 37: 1279-86.
23. Gonsberg F, Joos E, Geczy J. A pilot randomized placebo-controlled study of pirlindole in the treatment of primary fibromyalgia. J Musculoskelatal pain 1998; 6: 5-17.
24. Wolfe F, Cathey MA, Hawley DJA. Double-blind placebo controlled trial of fluoxetine in fibromyalgia. Scand J Rheumatol 1994; 23: 255-9.
25. Arnold LM, Hess EV, Hudson JI, Welge JA, Berno SE, Keck PE. A randomized, placebo-controlled, double-blind, flexible-dose study of fluoxetine in the treatment of women with fibromyalgia. Am J Med 2002; 112: 191-7.
26. Goldenberg D, Mayskiy M, Mossey C, Ruthazer R, Schmid C. A randomized double blind crossover trial of fluoxetine and amitriptyline in the treatment of fibromyalgia. Arthritis Rheum 1996; 39: 1852-9.
27. Ozerbil O, Okudan N, Gokbel H, Levendoglu F. Comparison of the effects of two antidepressants on exercise performance of female patients with fibromyalgia. Clin Rheumatol 2005; 1: 1-3.
28. Norregaard J, Volkmann H, Danneskiold-Samsoe A. A randomized controlled trial of citalopram in the treatment of fibromyalgia. Pain 1995; 61: 445-9.
29. Anderberg UM, Marteinsdottir I, von Knorring L. Citalopram in patients with fibromyalgia. A randomized, double-blind, placebo-controlled study. Eur J Pain 2000; 4: 27-35.
30. GlaxoSmithKline. Treatment of fibromyalgia: a randomized, double-blind, placebo-controlled study of paroxetine, a selective serotonin re-uptake inhibitor. Study ID 29060/443. 1995. Available at: htpp//ctr.gsk.co.uk/ Summary/paroxetine/studylist.asp.
31. Giordano N, Geraci S, Santacroce C et al. Efficacy and tollerabilità of paroxetine in patients with fibromyalgia sindrome: a single-blind study. Curr Therapeutic Res 1999; 60: 696-72.
32. Wetherhold EA, Carpenter DJ, Oakes R et al. A randomized, double-blind, triple crossover study of the independent and combined efficacy od paroxetine and nabumetone in the treatment of fibromyalgia. Presented at the 40° annual NCDEU meeting, Boca Raton, Florida, 2000.
33. Patkar AA, Masand PS, Krulewicz S, Mannelli P, Peindl K, Beebe KL, et al. A randomized, controlled, trial of controlled release paroxetine in fibromyalgia. Am J Med 2007; 120: 448-54.
34. Dwight MM, Arnold LM, O'Brien H, Metzger R, Morris-Park E, Keck PE. An open clinical trial of venlafaxine treatment of fibromyalgia. Psychosomatics 1998; 39: 14-7.
35. Sayar K, Aksu G, Ak I, Tosun M. Venlafaxine treatment of fibromyalgia. Ann Pharmacother 2003; 37: 1561-5.
36. Zijsltra TR, Barendregt PJ, van de Laar MA Venlafaxine in fibromyalgia: results of a randomized placebo-controlled, double-blind trial. Arthritis Rheum 2002; 46: S105.
37. Pitsikas N. Duloxetine. Curr Opin Investig Drugs 2000; 1: 116-21.
38. Westanmo AD, Gayken J, Haight R. Duloxetine: a balanced and selective norepinephrine-and serotoninreuptake inhibitor. Am J Health Syst Pharm 2005; 62: 2481-90.
39. Wernicke J, Lu Y, D'Souza DN, Waninger A, Tran P. Antidepressants: duloxetine at doses of 60 mg QD and 60 mg BID is effective in treatment of diabetic neuropathic pain (DNP). In: Abstracts of the 2nd Joint Scientific Meeting of the American Pain Society and the Canadian Pain Society. J Pain 2004; 5: S48.
40. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004; 50: 2974-2984.
41. Arnold LM, Rosen A, Pritchett YL, D'Souza DN, Goldstein DJ, Iyengar S, et al. A randomized, double-blind, placebo-controlled trial of duloxetine in the treatment of women with fibromyalgia with or without major depressive disorder. Pain 2005; 119: 5-15.
42. Arnold LM, Lu Y, Crofford LJ, Wohlreich M, Detke MJ, Iyengar S, Goldstein DJ. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder. Arthritis Rheum 2004; 50: 2974-84.
43. Gendreau RM, Mease PJ, Rao SR, Kranzler JD, Clauw DJ. Milnacipran: a potential new treatment of fibromyalgia. Arthritis Rheum 2003; 48: S616.
44. Gendreau RM, Thorn MD, Gendreau JF, Kranzler JD, Ribeiro S, Gracely RH, et al. Efficacy of Milnacipran in patients with fibromyalgia. J Rheumatol 2005; 32: 1975-85.
45. Vitton O, Gendreau M, Gendreau J, Kranzlen J, Rao SG. A double-blind placebo-controlled trial of Milnacipran in the treatment of fibromyalgia. Human Phsychophacol Clin Exp 2004; 1: 27-35.
46. Offenbaecher M, Ackenheil M. Current trends in neuropathic pain treatments with special reference to fibromyalgia. CNS Spectr 2005; 10: 285-97.
47. Krell HV, Leuchter AF, Cook IA, Abrams M. Evaluation of reboxetine, a noradrenergic antidepressant, for the treatment of fibromyalgia and chronic low back pain. Psychosomatics 2005; 46: 379-384.
48. Samborski W, Lezanska-Szpera M, Rybakowski JK. Effects of the antidepressant mirtazapine on fibromyalgia symptoms. Rocz Akad Med Bialymst 2004; 49: 265-9.
49. McQuay H, Carroll D, Jadad AR, Wiffen P, Moore A. Anticonvulsant drugs for management of pain: a systematic review. BMJ 1995; 311: 1047-52.
50. Backonia M, Glanzaman RL. Gabapentin dosing for neuropathic pain: evidence from randomized, placebo-controlled clinical trials. Clin Ther 2003; 25: 81-104.
51. Arnold LM, Goldenberg DL, Stanford SB Lalonde JK, Sandhu HS, Keck PE, et al. Gabapentin in the treatment of fibromyalgia: a randomized, double-blind, placebo-controlled, multicenter trial. Arthritis Rheum 2007; 56: 1336-44.
52. Crofford LJ, Rowbotham MC, Mease PJ, Russell IJ, Dworkin RH, Corbin AE, et al.: Pregabalin for the treatment of fibromyalgia syndrome: results of a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2005; 52: 1264-73.
53. Hocking G, Cousins MJ. Ketamine in chronic pain management: an evidence-based review. Anesth Analg 2003; 97: 1730-9.
54. Graven-Nielsen T, Aspegren Kendall S, Henriksson KG, Bengtsson M, Sarensen J, et al. Ketamine reduces muscle pain, tempural summation, and referred pain in fibromyalgia patients. Pain 2000; 85: 483-91.
55. Holman AJ. Treatment of fibromyalgia with the dopamine agonist Ropinirole: a 14 week double-blind pilot Randomized Controlled Trial (RCT) with 14-week Blinded Extension. Arthritis Rheum 2004; 49: S1870.
56. Holman AJ, Myers RR. A randomized, double-blind, placebo-controlled trial of pramipexole, a dopamine agonist, in patients with fibromyalgia receiving concomitant medications. Arthritis Rheum 2005; 52: 2495-505.
57. Rao SG, Bennett RM. Pharmacological treatment of fibromyalgia. Best Pract Res Clin Rheumatol 2003; 17: 611-27.
58. Pardi D, Black J. gamma-Hydroxybutyrate/sodium oxybate: neurobiology, and impact on sleep and wakefulness. CNS Drugs 2006; 20: 993-1018.
59. Scharf MB, Baumann M, Berkowitz DV. The effects of sodium oxybate on clinical symptoms and sleep patterns in patients with fibromyalgia. J Rheumatol 2003; 30: 1070-4.
60. Scharf MB, Hauck M, Stover R, McDannold M, Berkowitz D. Effect of gamma-hydroxybutyrate on pain, fatigue, and the alpha sleep anomaly in patients with fibromyalgia. Hydroxybutyrate preliminary report. J Rheumatol 1998; 25: 1986-90.
61. Biasi G, Manca S, Manganelli S, Marcolongo R. Tramadol in the fibromyalgia syndrome: a controlled clinical trial versus placebo. Int J Clin Pharmacol Res 1998; 18: 13-9.
62. Bennett RM, Kamin M, Karin R, Rosenthal N. Tramadol and acetaminophen combination tablets in the treatment of fibromyalgia pain. Am J Med 2003; 114: 537-45.
63. Bennett RM, Schein J, Kosinski MR, Hewitt DJ, Jordan DM, Rosenthal NR. Impact of fibromyalgia pain on health-related quality of life before and after treatment with tramadol/acetaminophen. Arthritis Rheum 2005; 53: 519-27.
64. Rowbotham MC, Twilling L, Davies PS, Reisner L, Taylor K, Mohr D. Oral opioid therapy for chronic peripheral and central neuropathic pain. N Engl J Med 2003; 348: 1223-32.
65. Magiakou MA, Chrousos GP. Corticosteroid therapy, nonendocrine disease, and corticosteroid withdrawal. Curr Ther Endocrinol Metab 1994; 5: 120-4.
66. Bennett RM, Clark SC, Walczyk MS. A randomised, double-blind, placebo-controlled study of growth hormone in the treatment of fibromyalgia. Am J Med 1998; 104: 227-31.
67. Finckh A, Berner IC, Aubry-Rozier B, So AK. A randomized controlled trial of dehydroepiandrosterone in postmenopausal women with fibromyalgia. J Rheumatol 2005; 32: 1336-40.
68. Stratz T, Farber L, Varga B, Baumgartner C, Haus U, Muller W. Fibromyalgia treatment with intravenous tropisetron administration. Drugs Exp Clin Res 2001; 27: 113-8.
69. Spath M, Stratz T, Neeck G, Kötter I, Hammel B, Amberger CC, et al.Efficacy and tolerability of intravenous tropisetron in the treatment of fibromyalgia. Scand J Rheumatol 2004; 33: 267-70.
70. Papadopoulos IA, Georgiou PE, Katsimbri PP, Drosos AA. Treatment of fibromyalgia with tropisetron, a 5HT3 serotonin antagonist: a pilot study. Clin Rheumatol 2000; 19: 6-8.
71. Koeppe C, Schneider C, Thieme, Mense S, Stratz T, Maller W, Flor H. The influence of the 5-HT3 receptor antagonist tropisetron on pain in fibromyalgia: a functional magnetic resonance imaging pilot study. Scand J Rheumatol 2004; 33: 24-7.
72. Wood PB, Kablinger AS, Caldito GS. Open trial of pindolol in the treatment of fibromyalgia. Ann Pharmacother 2005; 39: 1812-6.
73. Martinez-Lavin M. Management of dysautonomia in fibromyalgia. Rheum Dis Clin North Am 2002; 28: 379-87.
74. Buskila D, Neumann L. Genetics of fibromyalgia. Curr Pain Headache Rep 2005; 9: 313-5.
75. Frank B, Niesler B, Bondy B, Späth M, Pongratz DE, Ackenheil M, et al. Mutational analysis of serotonin receptor genes: HTR3A and HTR3B in fibromyalgia patients. Clin Rheumatol 2004; 23: 338-44.
76. Buskila D, Cohen H, Neumann L, Ebstein RP. An association between fibromyalgia and the dopamine D4 receptor exon III repeat polymorphism and relationship to novelty seeking personality traits. Mol Psychiatry 2004; 9: 730-1.
77. Sarzi-Puttini P, Buskila D, Carrabba M, Doria A, Atzeni F. Treatment strategy in fibromyalgia syndrome where are we now? Semin Arthritis Rheum 2007 (Epub ahead of print).
78. Staud R. Treatment of fibromyalgia and its symptoms. Expert Opinion Pharmather 2007; 8: 1629-42.